Search Labs

Drapkin Lab investigates the molecular drivers of oncogenesis, metastasis, and chemoresistance in small cell lung cancer (SCLC) to discover new therapeutic targets. 

The Acute Liver Failure Study Group (ALFSG) is a clinical research network funded by the National Institutes of Health since 1997, to gather important prospective data and biosamples on this rare condition. 

The focus of Dr. Agarwal's research has been on mechanisms of steroid action with emphases on: 1) structure-activity relationships of ligand-steroid receptor interactions, and 2) steroid metabolism.

The Arteaga laboratory has a longstanding interest in understanding the molecular pathways that drive breast cancer progression and influence response to therapies.

The Beckham lab is a dynamic multidisciplinary laboratory that studies viral pathogenesis and neuroimmune responses.

Dr. Bedimo studies strategies for optimally managing drug-resistant HIV patients, analyzing metabolic abnormalities in HIV patients, and studying the effects of HCV co-infection. 

We combine classical genetics with modern technology to understand human physiology and search for breakthrough treatments for diseases.

• To understand how kidney cancer develops at the molecular level.
• To translate our findings into new treatments for kidney cancer patients.
• To train the next generation of physicians and scientists.

Burstein Laboratory focuses on understanding the regulation of the inflammatory response at a molecular level, and elucidating how these events may participate in human disease.

The CDR Collaborative studies last mile delivery problems across the cancer control continuum to develop and implement solutions.

We conduct state-of-the-art clinical trials in the field of cardiovascular diseases, offering patients access to advanced clinical therapies that would otherwise not be available.

The global focus of the Cardiovascular Physiology Autonomic Function Laboratory is to examine the adaptive capacity of the circulation.

• We study the effects of exercise training, bed rest deconditioning, spaceflight, high altitude, aging, and the effects of cardiovascular diseases, such as heart failure.
• By using sophisticated tools to assess cardiovascular structure and function, our research team brings "Olympic" and "space age" science to the solution of common clinical problems such as fainting, hypertension, or patients with shortness of breath. 
• We focus on measuring how the cardio-respiratory system distributes oxygen from the environment to the muscles.
• Our facility is one of the few labs in the world that can measure the limitations to exercise capacity at every step along the "oxygen cascade" - including the lungs, heart and muscles.
• We use invasive and non-invasive tools to assess cardiovascular structure and function, as well as circulatory control mechanisms.

Kidney disease has reached epidemic proportions in the U.S. The Carroll Lab performs basic and translational research focused on kidney development, maintenance and regeneration. 

Our lab is creating better experimental models that reveal how cancer cells metastasize and evade our immune system. We use these models to develop new drugs that engage our immune system to kill cancer cells.

Our current research is focused on biochemical and structural studies of how membrane molecules signal to the actin cytoskeleton through a large, five-protein complex named the WAVE Regulatory Complex (WRC). 

Chung Lab uses primary human specimens, patient-derived xenograft models, and genetically engineered mouse models to study the molecular mechanisms underlying disease stem cell function in hematologic malignancies.

The discovery of ANP many years ago sparked interest in the use of natriuretic peptides to diagnose and treat heart failure and other salt-retaining disorders. Since then, there have been successes and failures. A more comprehensive understanding of the natriuretic peptide system, including the role of noncardiac factors such as race/ethnicity, may encourage more targeted approaches. One of the original insights of de Bold et al, was that the heart is an endocrine organ. Endocrine therapies are administered to individuals with specific evidence of endocrine dysfunction, not to capture short-term beneficial effects. For instance, thyroid hormone is given only to patients in whom hypothyroidism is demonstrated, not based on its metabolic actions. Studies are warranted to determine whether a similar strategy for the heart’s endocrine system can advance the prevention and treatment of cardiometabolic disease. CMRU is strategically positioned to advance research toward this important strategic goal. 

 In prior work, my laboratory focused on identifying novel mechanisms of therapy-resistance and progression in breast, prostate and ovarian cancer. 

The research focus in the Corbin lab investigates strategies that exploits the deviant metabolism of cancer cells (namely the reprogramming of lipid metabolism and altered redox biology) for therapeutic purposes.

The Cotter Research Group is a clinical lab focused on strategies to improve outcomes for patients with liver diseases with a particular focus on alcohol and metabolic dysfunction-associated liver diseases.